GlobeNewswire

Cisco 2018 Annual Cybersecurity Report Reveals Security Leaders Rely on and Invest in Automation, Machine Learning and Artificial Intelligence to Defend Against Threats

Dela

Findings show 39 percent of organizations are reliant on automation, 34 percent are reliant on machine learning, 32 percent are highly reliant on AI

SAN JOSE, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Malware sophistication is increasing as adversaries begin to weaponize cloud services and evade detection through encryption, used as a tool to conceal command-and-control activity. To reduce adversaries' time to operate, security professionals said they will increasingly leverage and spend more on tools that use AI and machine learning, reported in the 11th Cisco® 2018 Annual Cybersecurity Report (ACR).

While encryption is meant to enhance security, the expanded volume of encrypted web traffic (50 percent as of October 2017) - both legitimate and malicious - has created more challenges for defenders trying to identify and monitor potential threats. Cisco threat researchers observed more than a threefold increase in encrypted network communication used by inspected malware samples over a 12-month period.

Applying machine learning can help enhance network security defenses and, over time, "learn" how to automatically detect unusual patterns in encrypted web traffic, cloud, and IoT environments. Some of the 3,600 chief information security officers (CISOs) interviewed for the Cisco 2018 Security Capabilities Benchmark Study report, stated they were reliant and eager to add tools like machine learning and AI, but were frustrated by the number of false positives such systems generate. While still in its infancy, machine learning and AI technologies over time will mature and learn what is "normal" activity in the network environments they are monitoring.

"Last year's evolution of malware demonstrates that our adversaries continue to learn," said John N. Stewart, Senior Vice President and Chief Security and Trust Officer, Cisco. "We have to raise the bar now - top down leadership, business led, technology investments, and practice effective security - there is too much risk, and it is up to us to reduce it."

Cisco 2018 Annual Cybersecurity Report Additional Highlights

  • The financial cost of attacks is no longer a hypothetical number:
    • According to study respondents, more than half of all attacks resulted in financial damages of more than US$500,000, including, but not limited to, lost revenue, customers, opportunities, and out-of-pocket costs
       
  • Supply chain attacks are increasing in velocity, complexity
    These attacks can impact computers on a massive scale and can persist for months or even years. Defenders should be aware of the potential risk of using software or hardware from organizations that do not appear to have a responsible security posture.
    • Two such attacks in 2017, Nyetya and Ccleaner, infected users by attacking trusted software.
    • Defenders should review third-party efficacy testing of security technologies to help reduce the risk of supply chain attacks. 
  • Security is  getting more complex, scope of breaches is expanding
    Defenders are implementing a complex mix of products from a cross-section of vendors to protect against breaches. This complexity and growth in breaches has many downstream effects on an organization's ability to defend against attacks, such as increased risk of losses.
    • In 2017, 25 percent of security professionals said they used products from 11 to 20 vendors, compared with 18 percent of security professionals in 2016.
    • Security professionals said 32 percent of breaches affected more than half of their systems, compared with 15 percent in 2016.
  • Security professionals see value in behavioral analytics tools in locating malicious actors in networks
    • 92 percent of security professionals said behavior analytics tools work well. Two-thirds of the healthcare sector, followed by financial services, found behavior analytics to work extremely well to identify malicious actors.
       
  • Use of cloud is growing; attackers taking advantage of the lack of advanced security
    • In this year's study, 27 percent of security professionals said they are using off-premises private clouds, compared with 20 percent in 2016
    • Among them, 57 percent said they host networks in the cloud because of better data security; 48 percent, because of scalability; and 46 percent, because of ease of use.
    • While cloud offers better data security, attackers are taking advantage of the fact that security teams are having difficulty defending evolving and expanding cloud environments. The combination of best practices, advanced security technologies like machine learning, and first-line-of-defense tools like cloud security platforms can help protect this environment.
       
  • Trends in malware volume have an impact on defenders' time to detection (TTD)
    • The Cisco median TTD of about 4.6 hours for the period from November 2016 to October 2017 - well below the 39-hour median TTD reported in November 2015, and the 14-hour median reported in the Cisco 2017 Annual Cybersecurity Report for the period from November 2015 to October 2016.
    • The use of cloud-based security technology has been a key factor in helping Cisco to drive and keep its median TTD to a low level. Faster TTD helps defenders move sooner to resolving breaches.

Additional Recommendations for Defenders:

  • Confirm that they adhere to corporate policies and practices for application, system, and appliance patching.
  • Access timely, accurate threat intelligence data and processes that allow for that data to be incorporated into security monitoring.
  • Perform deeper and more advanced analytics.
  • Back up data often and test restoration procedures, processes that are critical in a world of fast-moving, network-based ransomware worms and destructive cyber weapons.
  • Conduct security scanning of microservice, cloud service, and application administration systems.

About the Report:
The Cisco 2018 Annual Cybersecurity Report, now in its 11th year, highlights findings and insights derived from threat intelligence and cybersecurity trends observed over the past 12-18 months from threat researches and six technology partners: Anomali, Lumeta, Qualys, Radware, SAINT, and TrapX. Also, included in the report are results of the annual Security Capabilities Benchmark Study (SCBS), which this year surveyed 3,600 chief security officers (CSOs) and security operations (SecOps) managers from 26 countries about the state of cybersecurity in their organizations.

Supporting Resources
Cisco 2018 Annual Cybersecurity Report
Cisco Blog: Setting the Cybersecurity Bar Higher - Announcing the Cisco 2018 Annual Cybersecurity
Cisco 2018 Annual Cybersecurity Report Graphics
In-Security video
Follow Cisco Security on Twitter @CiscoSecurity
Follow Cisco Security on LinkedIn 
Follow Cisco Security on Instagram
Like Cisco Security on Facebook

RSS Feed for Cisco:  http://newsroom.cisco.com/dlls/rss.html

About Cisco

Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.

Press Relations
Raquel Prieto
408-527-3754
raqpriet@cisco.com

Analyst Relations
Jenna Duston
408-424-7210
jeabeyta@cisco.com

Investor Relations
Marty Palka 
408-526-6635
mpalka@cisco.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum